[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Bluefin Biomedicine, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":46},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100615057","phase-2-a-study-evaluating-bfb759-in-moderate-to-severe-hidradenitis-suppurativa-100615057",false,"NCT07287644","A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa","A Phase 2, Dose Ranging, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of BFB759 in Patients With Moderate to Severe Hidradenitis Suppurativa","COMPASS 2-HS","Inclusion Criteria:\n\n* Are adults (18 to 75 years) with a diagnosis of hidradenitis suppurativa for at least one year.\n* Have moderate to severe disease not well controlled by systemic antibiotic treatment.\n* Are willing to follow study instructions, attend regular visits, and avoid certain other medications during the study.\n\nExclusion Criteria:\n\n* Have certain infections or other immune conditions.\n* Recently used medications that could interfere with the study.\n* Are pregnant or breastfeeding.","ALL","18 Years","75 Years",{"count":21,"type":22},210,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE2","PHASE3","This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.",[29],"Hidradenitis Suppurativa (HS)",[31,32],"Hidradenitis Suppurativa","acne inversa","RECRUITING","2026-05-28",{"date":36,"type":37},"2026-05-29","ACTUAL",{"date":39,"type":37},"2025-11-03",{"date":41,"type":22},"2027-08-01",{"name":43,"class":44},"Bluefin Biomedicine, Inc.","INDUSTRY",58,""]